Drug Profile
Enobosarm - Veru Healthcare
Alternative Names: GTx-024; MK-2866; Ostarine; S-22; VERU-024Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Ohio State University Research Foundation; University of Tennessee Research Foundation
- Developer Oncternal Therapeutics, Inc.; Veru Healthcare
- Class Antineoplastics; Nitriles; Small molecules; Urologics
- Mechanism of Action Selective androgen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Breast cancer
- Discontinued Cachexia; Duchenne muscular dystrophy; Muscular atrophy; Stress incontinence
Most Recent Events
- 08 Mar 2024 GTx terminates a phase II trial in Breast cancer (Metastatic disease) in USA (PO) (NCT01616758)
- 28 Feb 2024 Veru Inc plans to initiate a phase II trial for Obesity (Treatment experienced) in April 2024 (NCT06282458)
- 23 Feb 2024 Veru Healthcare terminates the phase III VERU-024 trial in Breast cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (PO, Capsule) due to business decision (NCT05065411)